Encouraging data for Roche multiple sclerosis injection
EU approval for Roche’s subcutaneous OCREVUS is anticipated mid-2024, depending on acceptance of regulatory submission.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
